PRQR•ProQR Therapeutics’ third-quarter 2026 net loss widened 13% year over year to €12.4 million, while research and development costs rose 29% to €14.3 million. The company had €103 million in cash and cash equivalents at September 30, supporting operations into mid-2028.
ProQR Therapeutics reported a third-quarter 2026 net loss of €12.4 million, up 13% year over year, and research and development costs of €14.3 million, up 29%. Cash and cash equivalents totaled €103 million at September 30, which the company said supports operations into mid-2028. AX-0811’s first two Phase 1 cohorts are fully enrolled, with initial target engagement data expected in early January 2027; the full AX-0810 Phase 1 dataset, including Cohort 3 and follow-up data, is expected in December 2026.
